Structural Heart Disease | Implantable Devices for Heart Valve Repair
Type of Organization: Private (Venture and Private Equity Financed)
Year of Incorporation: 2004
MiCardia has developed a new-to-world technology platform to dynamically optimize mitral valve repair, during and after surgery, to achieve the proper shape and size necessary to produce superior clinical outcomes for each patient. CE Mark for the enCorSQ™ Mitral Valve Repair System™ was received in September, 2011. The first patient to be adjusted was successfully treated in August, 2011, four months after implant.
- Jeff DuMontelle Vice President and General Manager
Investors: Please contact Jeff DuMontelle